Chemotherapy Induced Peripheral Neuropathy (CIPN)

Chemotherapy Induced Peripheral Neuropathy (CIPN) is anticipated for the majority of breast cancer patients who receive neurotoxic chemotherapy, depending on the agent used, dose and schedule.  Numbness, tingling and pain in the hands and feet can develop with CIPN.  If severe, CIPN can cause weakness and functional limitations.  Anodyne therapy, a relatively new treatment for peripheral neuropathy can improve sensation and decrease pain.  Early identification of symptoms and initiation of treatment results in improved treatment outcomes.